Regenicin, Inc.
RGIN · OTC
9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.27 | 0.17 | -0.09 |
| FCF Yield | -5.56% | -0.79% | -6.69% | -4.35% |
| EV / EBITDA | -1.86 | -5.77 | -4.73 | -4.57 |
| Quality | ||||
| ROIC | 12.13% | 14.60% | 13.77% | 23.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.04 | 0.03 | 0.22 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -13.21% | 80.43% | 2.89% | 5.13% |
| Safety | ||||
| Net Debt / EBITDA | -1.05 | -0.95 | -1.13 | -0.62 |
| Interest Coverage | -16.58 | -18.32 | -10.86 | -41.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -62.61 | 0.00 | 0.00 | 0.00 |